Genomics and patient selection in the treatment of mPCa patients

In this interview from UROonco24, Dr. Juan Gómez Rivas (ES) and Dr. Ursula Vogl (CH) discuss advancements in genomic profiling and the use of PARP inhibitors in treating metastatic prostate cancer, with a focus on genomic profiling, patient selection and toxicity management.This activity is supported by an educational grant from a Pharmaceutical company, with no involvement in the programme or speaker selection.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.